KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Non-Current Assets (2016 - 2025)

Charles River Laboratories International (CRL) has 15 years of Non-Current Assets data on record, last reported at $6.1 billion in Q1 2025.

  • For Q1 2025, Non-Current Assets rose 464.23% year-over-year to $6.1 billion; the TTM value through Mar 2025 reached $17.0 billion, down 2.11%, while the annual FY2024 figure was $6.1 billion, 7.0% down from the prior year.
  • Non-Current Assets reached $6.1 billion in Q1 2025 per CRL's latest filing, down from $6.1 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $6.6 billion in Q4 2023 and bottomed at -$1.7 billion in Q1 2024.
  • Average Non-Current Assets over 5 years is $4.7 billion, with a median of $6.1 billion recorded in 2023.
  • Peak YoY movement for Non-Current Assets: dropped 7.0% in 2024, then soared 464.23% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $5.8 billion in 2021, then grew by 7.19% to $6.2 billion in 2022, then rose by 6.86% to $6.6 billion in 2023, then decreased by 7.0% to $6.1 billion in 2024, then dropped by 0.8% to $6.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $6.1 billion in Q1 2025, $6.1 billion in Q4 2024, and $6.4 billion in Q2 2024.